The Lake Oswego, OR-based company received a nod from FDA for the coronary stent system in September of 2018 but launched the device this month to coincide with the release of Orsiro, its ultrathin strut DES.
The move comes about a week after the San Diego-based company revealed it would cut 50% of its workforce.
Solana Beach, CA-based Puregraft has developed a technology that would use a person’s own fat for breast augmentation or restructuring.
The Rolling Stones frontman’s recent procedure has brought a great deal of awareness to the TAVR market, which could be beneficial to device makers in the space.
The Palo Alto, CA-based company has received FDA clearance for a wearable that can remotely monitor patients with chronic diseases, such as chronic obstructive pulmonary disease (COPD), allowing the detection of early signs of deterioration before symptoms are noticeable.
Alcon performed extremely well on the market trading at $57.81 a share, giving the eye-care company a value of nearly $29 billion.
The company said that it will integrate its Edison platform with the American College of Radiology, Artificial Intelligence-Lab.
The Galway, Ireland-based company’s technology is a minimally invasive approach toward treating anal fistula.
Cellgen Diagnostics and Genomic Testing Cooperative announced a collaboration that promises to provide the pharmaceutical industry with the seamless integration of biomarker discovery, validation, and IVD development.
The San Diego, CA-based company is set eliminate all of its direct sales force and some of its headquarters staff in a move that could reduce operating expenses in 2Q19 by about 35%.
The company said the Extended Wear Medical Transfer Adhesive 4075 offers initial skin adhesion with up to a 14-day wear time, depending on the backing material used.
If Chembio Diagnostics and Perseus Science Group are able to get a test on the market, the two would directly compete against Banyan Biomarkers, a company that received a nod from FDA for a concussion test platform last year.
The Marlborough, MA-based company has secured CE mark for its HeartLight X3 and said it has seen triple-digit growth for its atrial fibrillation treatment technologies.
The San Diego-based company is alleging that some of BGI’s sequencing products infringe on a patent that covers Illumina’s sequencing-by-synthesis chemistry.